Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug The Swiss company said the 89bio candidate could complement its obesity pipeline (Sep 18, 2025) by Andrew Joseph. LONDON — Roche on Thursday said it would buy 89bio, the maker of an experimental drug for a liver disease that’s attracted increasing pharma interest, in a deal

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate (Sep 8, 2025) by Darren Incorvaia. Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for a rare genetic disease. The French pharma is offering as much as $450 million for KER-0193, a potential therapy for Fragile X syndrome. Kaerus

Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity; CTA to be filed in 2H 2025 (Sep 04, 2025) by Congruence Therapeutics. MONTREAL, Sept. 4, 2025 /PRNewswire/ — Congruence, a computationally-driven biotechnology company building a unique

Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal (Aug 28, 2025) by Darren Incorvaia. As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration with Replicate Bioscience, potentially